INSIGHTS ON CELL & GENE CLINICAL TRIALS
De-Risking Cell And Gene Therapy Clinical Trials
Ohio State University Gene Therapy Institute's Dr. Russell Lonser explains five major reasons for the early failures in direct delivery gene therapy trials, methods and technologies to increase the efficacy of direct drug delivery, and more.
In Silico Modeling Unveils A New Era In Rare Disease Drug Development
Gain insights into how innovative silico modeling is revolutionizing rare disease drug development and opening new possibilities for accelerated research.
Evaluating A CRO For Rare Disease Studies: A Checklist For Success
When launching an RFP, refer to this checklist to ensure comprehensive coverage of all aspects when evaluating potential research partners for the rare disease study.
Early Planning To De-Risk Development: Strategy & Study Design
Access insightful guides and checklists that provide valuable advice and best practices for planning and executing effective nonclinical studies.
RNA Therapies – Global Clinical Trial Landscape - Focus On Asia Pacific
Learn about the global clinical trial landscape of RNA therapy, with emphasis on trends in the Asia Pacific, and recent advancements in the field.
The Potential Of Prime Editing
Ann L. Lee, Ph.D., Chief Technical Officer at Prime Medicine explains prime editing’s potential to make wholesale changes to DNA at one time.
The Cell & Gene Therapy Clinical Trials Global Landscape
Gain valuable insights into the current state of cell and gene therapy clinical trials and the opportunities and challenges in this rapidly evolving field.
What Are The Benefits Of A Well-Designed, Robust Preclinical Development Plan?
Discover how a well-designed and robust preclinical development plan can help identify potential safety and efficacy issues early in the drug development process, ultimately reducing the risk of failure in clinical trials.
Phase I Trials Global Clinical Trial Landscape – Focus On Asia Pacific
Discover key trends in global Phase I trials, including highlights from the top therapeutic areas, indications, and biologic drug types in the last five-year period in popular trial regions of Asia Pacific, the United States, and Europe.
Multi-Specific Monoclonal Antibodies – Global Clinical Trial Landscape - Focus On Asia Pacific
Learn about the global clinical trial landscape of multi-specific monoclonal antibodies (Mabs), with emphasis on trends in the Asia Pacific, and recent advancements in the field.